US4424211A
Expired / Lapsed
US
⏱️ 0.0 years remaining
2'Deoxy-5-(2-halogenovinyl)-uridines, pharmaceutical compositions and method of use
Assignee: Stichting Rega VZW
•
Filing: 1981-12-21
•
Granted: 1984-01-03
•
Expires: 2001-12-21
Abstract
Abstract The novel substance E-5-(2-bromovinyl)-2'-deoxyuridine and its corresponding iodovinyl derivative are gifted with specific antiviral activities towards herpes simplex virus. They may be synthesized by a condensation reaction followed by separation of anomers.
Inventors
- 👤 Albert S. Jones
- 👤 Richard T. Walker
- 👤 Erik D. A. de Clercq
- 👤 Philip J. Barr
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 12:36
CPC Classifications
C; C07; C07H; C07H19/00; C07H19/02; C07H19/04; C07H19/06; A; A61; A61P; A61P31/00; A61P31/12; C07F; C07F7/00; C07F7/02; C07F7/08; C07F7/18; C07F7/1804
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
20 words
E-5(2-halogenovinyl)-2'-deoxyuridines of the formula: ##STR3## wherein Hal represents a halogen atom selected from the group consisting of bromine and iodine.
Claim 2
Dependent Claim
20 words
E-5(2-halogenovinyl)-2'-deoxyuridines of the formula: ##STR3## wherein Hal represents a halogen atom selected from the group consisting of bromine and iodine.
Claim 3
Dependent Claim
10 words
An E-5-(2-halogenvinyl)-2'-deoxyuridine as in claim 1, wherein Hal represents bromine.
Claim 4
Dependent Claim
10 words
An E-5-(2-halogenovinyl)-2'-deoxyuridine as in claim 1, wherein Hal represents iodine.
Claim 5
Dependent Claim
50 words
A pharmaceutical composition for the treatment of herpes simplex infections comprising as an active ingredient an antiviral effective amount of an E-5-(2-halogenovinyl)-2'-deoxyuridine compound of the formula: ##STR4## wherein Hal represents a halogen atom selected from the group consisting of bromine and iodine, and a pharmaceutically acceptable carrier, diluent or excipient.
Claim 6
Dependent Claim
50 words
A pharmaceutical composition for the treatment of herpes simplex infections comprising as an active ingredient an antiviral effective amount of an E-5-(2-halogenovinyl)-2'-deoxyuridine compound of the formula: ##STR4## wherein Hal represents a halogen atom selected from the group consisting of bromine and iodine, and a pharmaceutically acceptable carrier, diluent or excipient.
Claim 7
Dependent Claim
11 words
A pharmaceutical composition as in claim 4, wherein Hal represents bromine.
Claim 8
Dependent Claim
11 words
A pharmaceutical composition as in claim 4, wherein Hal represents iodine.
Claim 9
Independent Claim
36 words
A method for treating herpes simplex infections comprising administering an effective antiviral amount of an E-5-(2-halogenovinyl)-2'-deoxyuridine compound of the formula: ##STR5## wherein Hal represents a halogen atom selected from the group consisting of bromine and iodine.
Claim 10
Independent Claim
36 words
A method for treating herpes simplex infections comprising administering an effective antiviral amount of an E-5-(2-halogenovinyl)-2'-deoxyuridine compound of the formula: ##STR5## wherein Hal represents a halogen atom selected from the group consisting of bromine and iodine.
Claim 11
Dependent Claim
15 words
The method for treating herpes simplex infections according to claim 7, wherein Hal represents bromine.
Claim 12
Dependent Claim
15 words
The method for treating herpes simplex infections according to claim 7, wherein Hal represents iodine.
References Cited (Backward Citations)
US3748320A
Cited
US3817980A
Cited
US3891623A
Cited
US4093715A
Cited
US4093716A
Cited
US4182859A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-01-02 | 1987-07-04 | 1988-01-03 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-01-02 | 1991-07-04 | 1992-01-03 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-01-02 | 1995-07-04 | 1996-01-03 | $7700.00 | Window Closed / Lapsed |